Keytruda Adjuvant Combinations
Multiple Solid Tumors (Adjuvant Setting)
Sponsor Merck (MSD)
8,500 Enrollment Target
450 Trial Sites
6 Countries
December 2029 Est. Completion
About This Trial
Master protocol evaluating pembrolizumab combinations across 12 tumor types in adjuvant setting.
Primary Endpoints
- Disease-free survival
- Overall survival
Latest Update
February 2026
Positive results in renal cell carcinoma arm. Two additional tumor types showing promising interim data.